TigerText Launches Role-based Scheduling Automation Feb 16, 2017 TigerText Automated role assignments and dynamic scheduling speed clinical communication among teams, enabling faster shift transitions and patient handoffs Power of Role-based Scheduling showcased...
Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes Boston, MA – February 3, 2017 – Intarcia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B Evidence of High-Efficiency Liver Transduction with...
Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer NEW HAVEN, Conn., January 5, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it...
Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity Collaboration aims to develop a novel peptide therapeutic derived from Calibr’s Stapled-Peptide Technology Platform that...
Recent Comments